Family Hereditary Cancer: IVF Screening in Kyrgyzstan, PGT Gene Testing to Block Inheritance

Real consultation scenario opening (Mechanism 1)

This question involves preimplantation genetic testing for monogenic diseases (PGT-M) in the field of assisted reproduction. The following explains from four dimensions: clinical process, technical principles, applicable conditions, and risk warnings.

========== A Direct Answer ==========

Direct Answer to the Question

For patients with family hereditary cancer, PGT screening during IVF in Kyrgyzstan can significantly reduce the risk of passing on the pathogenic gene to the next generation, but it cannot guarantee 100% prevention.

The accuracy of PGT-M (monogenic disease testing) for known pathogenic genes ranges from 95% to 99%, mainly influenced by the following factors:

• Embryo biopsy quality — number of biopsied cells and uniformity of amplification
• Gene testing platform precision — NGS sequencing depth and data analysis algorithms
• Embryo mosaicism ratio — low-level mosaicism may lead to missed detection
• Inheritance pattern of the pathogenic gene — different testing strategies for dominant and recessive inheritance

After transferring an embryo with a "not a carrier" result, the probability of the offspring developing this hereditary cancer decreases from 50% (autosomal dominant inheritance) to a level close to the general population. However, it is important to note: PGT only targets specific known pathogenic sites and does not rule out other genetic risks.

========== C Doctor's Perspective ==========

Doctor's Perspective: Accuracy and Limitations of PGT

From a reproductive medicine perspective, PGT-M is one of the most effective methods for blocking monogenic genetic diseases, but the following points must be clarified:

Testing Accuracy

• Testing Platform: Primarily NGS (next-generation sequencing) combined with SNP linkage analysis, accuracy >98%
• Testing Strategy: Direct detection of pathogenic sites + haplotype linkage analysis to reduce the risk of allele dropout (ADO)
• Verification Method: All PGT pregnancies are recommended to undergo mid-trimester amniocentesis for verification

Technical Limitations

• Embryo mosaicism may lead to discrepancies between test results and actual genotype
• There is a 0.5%–2% misdiagnosis rate (including false positives and false negatives)
• Cannot detect de novo mutations
• Does not cover unknown pathogenic genes; only targets clearly identified familial mutations

Clinical Recommendation: Prenatal diagnostic verification is mandatory after PGT-M pregnancy. Offspring should have regular follow-ups after birth, which cannot replace routine health management.

========== E Differences Between Countries ==========

Differences in Policies and Costs Between Countries

Regulations and fee structures for PGT vary significantly between countries. The following is a comparison of common destinations:

Country/Region	PGT Legal Policy	Cost Range (Per Cycle)	Notes
Kyrgyzstan	PGT-M (monogenic disease testing) permitted	80,000–150,000 CNY	Some hospitals outsource genetic testing; verify lab qualifications
China	Strictly limited medical indications	100,000–200,000 CNY	Requires hospital ethics approval; longer cycle
Thailand	PGT-M permitted	120,000–200,000 CNY	Requires referral through formal medical institutions
United States	PGT-M permitted, lenient policies	250,000–400,000 CNY	High testing costs; must contact lab independently
Georgia	PGT-M permitted	80,000–120,000 CNY	Assess embryo lab experience

Considerations for Choosing Kyrgyzstan: Relatively lower cost, small time difference with China (approx. 2 hours), some reproductive centers offer Russian/Chinese translation services. However, it is necessary to confirm whether the hospital has full PGT process capability, whether genetic testing is outsourced, and the certification status of the outsourced laboratory.

========== I Actual Process ==========

Actual Process of IVF Screening in Kyrgyzstan

The following is the standardized PGT-M process, explained step by step:

Step 1: Genetic Counseling and Gene Confirmation (Recommended to complete in home country)

• Identify the pathogenic gene mutation site in the family (requires proband sample)
• Proband (affected family member) undergoes whole exome or targeted gene sequencing
• Couple undergoes carrier verification to determine inheritance pattern

Step 2: Pre-IVF Preparation (Kyrgyzstan)

• Couple's medical examinations: hormone panel (FSH, LH, E2, etc.), AMH, semen analysis, infectious disease screening, karyotype
• Sign PGT informed consent form, confirm testing scope
• Establish medical record and develop individualized ovarian stimulation protocol

Step 3: Ovarian Stimulation and Egg Retrieval

• Start ovarian stimulation on day 2–3 of menstruation (average 10–14 days)
• Egg retrieval surgery (intravenous anesthesia, transvaginal ultrasound-guided)
• Sperm collection (performed on the same day as egg retrieval, usually by masturbation)

Step 4: In Vitro Fertilization and Embryo Culture

• ICSI (intracytoplasmic sperm injection) for fertilization to avoid polyspermy
• Embryo culture to blastocyst stage (day 5–6)
• Blastocyst biopsy: removal of 3–5 cells from the trophectoderm

Step 5: Genetic Testing

• Biopsied cells sent for PGT-M (testing period 7–14 days)
• Test report issued, clarifying the carrier status of the pathogenic gene for each embryo

Step 6: Embryo Transfer

• Select blastocysts not carrying the pathogenic gene for frozen-thawed embryo transfer (FET)
• Luteal phase support after transfer (progesterone medications)

Step 7: Pregnancy Follow-up

• Blood hCG pregnancy test 12–14 days after transfer
• Mid-trimester amniocentesis for verification (strongly recommended)

========== J Timeline ==========

Timeline and Required Documents

Stage	Time Required	Notes
Genetic counseling and gene confirmation in home country	1–2 months	Proband testing + couple verification; prerequisite condition
Pre-IVF examinations in Kyrgyzstan	2–4 weeks	Some tests can be completed at a tertiary hospital in home country
Ovarian stimulation and egg retrieval	2–3 weeks	Requires stay in Kyrgyzstan
Embryo culture and biopsy	5–6 days	Lab culture to blastocyst stage
Genetic testing	1–2 weeks	Testing period depends on the lab
Frozen embryo transfer	1–2 months	Scheduled according to endometrial cycle
Total duration	3–5 months	Includes preparation and waiting window

List of required documents:

• Passports of both spouses (valid for at least 6 months)
• Notarized marriage certificate with Russian/English translation
• Genetic test report from home country (Chinese and English versions)
• Family cancer history documents (medical records, diagnosis certificates, genetic reports)
• Pre-IVF medical examination reports (recommend translation in advance)

========== H Common Pitfalls ==========

Easily Overlooked Details and Common Misconceptions

Misconception 1: PGT can test for all cancer genes

PGT-M only targets known, specific pathogenic gene mutations. It cannot detect unknown genes or cancers with complex inheritance. Polygenic inheritance and sporadic cancers caused by environmental factors are not within the testing scope.

Misconception 2: Embryos with normal results will never develop cancer

PGT-M only reduces the risk of specific hereditary cancers. Offspring may still develop other types of cancer (including those caused by de novo mutations or environmental factors).

Misconception 3: All hospitals in Kyrgyzstan can perform PGT

Performing PGT requires both embryo lab qualifications and a genetic testing platform. Not all reproductive centers have these. Before choosing, confirm whether the hospital has successful PGT-M cases and whether genetic testing is done in-house or outsourced.

Easily Overlooked Details

• Proband genetic testing is a prerequisite: If no family member has undergone genetic testing, the specific pathogenic site cannot be identified, and PGT cannot proceed.
• Embryos must be frozen after biopsy: Test results take time; embryos need to be cryopreserved until a suitable transfer cycle.
• Psychological preparation: It is possible that all embryos carry the pathogenic gene, resulting in no transferable embryos (incidence 5%–15%, depending on mutation type).
• Test report validity: Some hospitals require genetic test reports to be within 6 months; re-testing may be needed if expired.

========== M Case Scenario Analysis ==========

Case Scenario Analysis

Case 1: BRCA1 Mutation Carrier — Successful Blocking

A 32-year-old woman, carrier of the BRCA1 c.5266dupC mutation, whose mother was diagnosed with ovarian cancer at age 45. The couple completed a PGT-M cycle in Kyrgyzstan: 15 eggs retrieved, 8 blastocysts formed, 3 found not to carry the mutation after testing. One embryo was transferred, resulting in a successful pregnancy. Prenatal diagnosis confirmed the fetus did not carry the BRCA1 mutation.

Case 2: Lynch Syndrome — Second Transfer Needed

A 28-year-old man, carrier of the MLH1 gene mutation, whose father and uncle both had colorectal cancer. The couple went to Kyrgyzstan for PGT-M: 12 eggs retrieved, 6 blastocysts, testing revealed 2 without the mutation. One transfer did not result in pregnancy; one embryo remains frozen for a second transfer. This indicates PGT success depends not only on testing but also on embryo quality and uterine receptivity.

Case 3: No Transferable Embryos — Advance Planning

A 35-year-old woman, carrier of the TP53 gene mutation (Li-Fraumeni syndrome). 20 eggs retrieved, 10 blastocysts, all 10 carried the TP53 mutation after PGT-M testing, leaving no transferable embryos. This occurs in about 10%–20% of dominant inheritance cases. It is recommended to prepare alternative plans in advance: egg/sperm donation, another ovarian stimulation cycle, or natural pregnancy followed by prenatal diagnosis.

========== Q Frequently Asked Questions ==========

Frequently Asked Questions

========== Risk Reminder (Ending) ==========